RxDoctor Payments Data

Davonnie Dunn, MD

Family Medicine · Columbus, NJNPI 1144302530

Payments from drug & device makers

$6,385in general payments, 2019–2025

Across 442 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$793
  • AstraZeneca$363
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$270
  • Axsome Therapeutics, Inc.$259
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,379100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,385 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$107,078
Medicare patients
293
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate67$77,175
MounjaroTirzepatide39$55,503
JardianceEmpagliflozin41$48,242
OzempicSemaglutide22$37,300
EliquisApixaban31$33,497
TrulicityDulaglutide21$28,752
RybelsusSemaglutide15$28,336
FarxigaDapagliflozin Propanediol18$17,436
XareltoRivaroxaban11$12,692
Breo ElliptaFluticasone/Vilanterol20$10,418
GeodonZiprasidone Hcl12$8,995
LinzessLinaclotide12$6,355
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,084
Icosapent Ethyl11$4,972
Levothyroxine Sodium306$3,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$793$84,25560 claims
MerckJanuvia$111$77,17567 claims
Novo NordiskOzempic, Rybelsus$1,125$65,63637 claims
Boehringer IngelheimJardiance$54$48,24241 claims
PfizerEliquis, Geodon$40$42,49243 claims
AstraZenecaFarxiga$363$17,43618 claims
GSKBreo Ellipta, Anoro Ellipta$15$15,50131 claims
Johnson & JohnsonXarelto$113$12,69211 claims
AbbVieLinzess, Synthroid$1,347$8,46243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Columbus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →